AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEW ORLEANS -- Paroxetine was linked to significant reductions in the frequency and severity of hot flashes in menopausal women in a randomized, double-blind, placebo-controlled trial.
The findings suggest that the selective serotonin reuptake inhibitor, which is marketed as Paxil, may serve as a good alternative to hormone replacement therapy (HRT) for the treatment of hot flashes, Dr. Vered Stearns reported in a poster presentation at the annual meeting of the American College of Obstetricians and Gynecologists.
In the multicenter study of 165 peri- and postmenopausal patients, the mean daily hot flash composite score--a measure of the frequency and severity of daily hot flashes--dropped by 62% in those randomized to receive low-dose (12.5 mg/day) controlled-release (CR) paroxetine and by 65% in those in a high-dose paroxetine CR (25 mg/day) group during the 6-week treatment period. The score dropped by only 38% in the placebo group, said Dr. Stearns of Johns Hopkins University, Baltimore.
Clinically and statistically significant reductions in daily hot flash composite scores were noted within 1 week in both paroxetine groups, and more than 60% of patients in the paroxetine groups had at least a 50% reduction in hot flash frequency and severity by week 6.
Paroxetine CR was well tolerated in this study, which was sponsored by Glaxo-SmithKline, the maker of Paxil. ...
Source: HighBeam Research, Paxil tied to drop in hot flash severity, frequency.(Decreased by at...